Full results of the study are now available online and will publish in the July printing issue of Arthritis Care & Research, a journal of the American University of Rheumatology. RA, a chronic inflammatory disease characterized by swollen joints, discomfort, stiffness, fatigue, and general malaise affects up to 1 percent of the global population, according to the World Health Company . The Centers for Disease Control and Avoidance citing health-related quality of life studies discovered that RA sufferers were 40 percent much more likely to statement fair or poor health and wellness and twice as more likely to possess a health-related activity limitation weighed against those without arthritis.The randomized, controlled, double-blinded study included platelet-deficient cancer individuals at four medical centers in Spain, the United Kingdom, Sweden and France. The trial fulfilled its primary endpoint, defined as statistical non-inferiority of the INTERCEPT platelet one-hour corrected count increment in comparison to conventional platelet elements. The corrected count increment actions the upsurge in the patient’s platelet count following a platelet transfusion, adjusted for dose and patient blood volume. The complete difference in one-hour corrected count increment between the INTERCEPT and control groupings was approximately 13 %, similar to differences seen in previous research.